Related Experiment Video

Updated: Sep 16, 2025

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

3.9K

Back to normal: super-response to mavacamten in a patient with obstructive hypertrophic cardiomyopathy

Tobia Albertini1,2, Alain M Bernheim3, Annina A Studer Bruengger3,4

  • 1Department of Cardiology, Stadtspital Zürich, Zurich, Switzerland. tobia.albertini@gmail.com.

The International Journal of Cardiovascular Imaging
|July 7, 2025
PubMed

Insights

Mavacamten effectively treats hypertrophic cardiomyopathy (HCM) by reducing left ventricular outflow tract obstruction and mitral regurgitation. This cardiac myosin inhibitor also led to a significant decrease in left ventricular mass in a patient case study.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease.
  • It often causes left ventricular hypertrophy, outflow tract obstruction, and mitral regurgitation.
  • Systolic anterior motion of the mitral valve is a key mechanism.

Purpose of the Study:

  • To evaluate the efficacy of mavacamten in a patient with HCM.
  • To assess the impact of mavacamten on left ventricular outflow tract (LVOT) obstruction and mitral regurgitation (MR).
  • To observe changes in left ventricular (LV) mass.

Main Methods:

  • Case report presentation.
  • Treatment with mavacamten, a cardiac myosin inhibitor.
  • Monitoring of hemodynamic parameters and cardiac imaging.

Main Results:

  • Mavacamten significantly reduced LVOT obstruction.
  • Mavacamten markedly decreased mitral regurgitation.
  • Normalization of left ventricular mass was observed.

Conclusions:

  • Mavacamten demonstrates significant therapeutic potential in managing HCM.
  • This treatment effectively addresses key pathophysiological aspects of HCM, including obstruction and regurgitation.
  • Mavacamten may reverse cardiac remodeling in HCM patients.

Keywords:
Hypertrophic cardiomyopathy with left ventricular outflow tract obstructionMavacamtenMitral valve systolic anterior motionMyosin inhibitor

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K
Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

24.7K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
61
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
39
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
38
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
516
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
71